Single-Center Experience of 500 Cases of Laparoscopic Sleeve Gastrectomy: Surgical Techniques and Perioperative Management Strategies.

Introduction: Reported results and techniques of laparoscopic sleeve gastrectomy (LSG) are variable. Our objective was to assess results of weight loss, complications, and reflux in a large consecutive series of LSG, describing technical detail which contributed to outcomes. Methods: Retrospective review of prospectively collected data of 500 consecutive patients undergoing LSG. Patient demographics, weight loss, complications, and functional outcomes were analyzed and operative technique described. Results: Five hundred patients underwent LSG over 3 years (2 revisional). Mean (range) preoperative body mass index was 40 kg/m2 (32-75 kg/m2). Mean follow-up and length of hospital stay were 12 months (1-36) and 7.2 days (5-12), respectively. All-cause 30-day readmission rate was 0.3%. Mean excess weight loss was 22.3% (1 month), 42.2% (3 month), 57.2% (6 month), and 73.1% (1 year). There was no mortality and intraoperative complications occurred in our 500 cases. Early surgical complications in 2 (0.2%) patients (postoperative bleeds). Gastro-oesophageal reflux symptoms decreased about 10%. Conclusion: With attention to detail, LSG can lead to good excess weight loss with minimal complications. Tenants to success include repair of hiatal laxity, generous width at angula incisura, and complete resection of posterior fundus.

Molecular magnetic resonance probe targeting VEGF165: preparation and in vitro and in vivo evaluation.

A new method for imaging the tumor human vascular endothelial growth factor 165 (VEGF 165) is presented. A magnetic resonance imaging (MRI) probe was prepared by crosslinking ultrasmall superparamagnetic iron oxide (USPIO) nanoparticles to the aptamer for tumor vascular endothelial growth factor 165 (VEGF165-aptamer). The molecular probe was evaluated for its in vitro and in vivo activities toward VEGF165. Enzyme-linked immunosorbent assay showed that the VEGF165-aptamer-USPIO nanoparticles conjugate specifically binds to VEGF165 in vitro. A cell proliferation test showed that VEGF165-aptamer-USPIO seems to block the proliferation of human umbilical vein endothelial cells induced by free VEGF165, suggesting that VEGF165 is an effective target of this molecular probe. In xenograft mice carrying liver cancer that expresses VEGF165, T2-weighted imaging of the tumor displayed marked negative enhancement 3 h after the intravenous administration of VEGF165-aptamer-USPIO. The enhancement disappeared 6 h after administration of the probe. These results suggest the targeted imaging effect of VEGF165-aptamer-USPIO probe in vivo for VEGF165-expressing tumors. This is the first report of a targeted MRI molecular probe based on USPIO and VEGF165-aptamer.